Camurus (CAMX) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Oczyesa to treat patients with acromegaly, a disease stemming from the pituitary gland.
CHMP's positive opinion is backed by seven clinical trials of the potential drug, which showcased a "higher proportion" of patients who responded to treatment with somatostatin analogues, achieving normalized insulin growth-factor-1 levels versus placebo groups, the company said.
One of the studies also showed improvement in symptoms and quality of life, according to a statement.
The company said a final decision on the market authorization is expected from the European Commission mid-year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.